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Activation of the immune system against protozoan infections relies particularly on two speciﬁc signals provided by cognate in-
teraction of T cells with antigen presenting cells (APCs). The ﬁrst signal is attributed to binding of the T-cell receptor (TCR)
to peptide/MHC complexes on the surface of APCs, whereas the second signal is triggered through binding of several cos-
timulatory molecules on the surface of APCs with their corresponding receptors on T cells. Among these costimulatory sig-
nallings, CD40/CD40L interactions have been particularly investigated in protozoan infection models with regard to their po-
tential to amplify cell-mediated immunity against intracellular parasites. This article reviews current studies of the potential role
of CD40/CD40L interaction in the modulation of immune responses against some protozoan parasites and highlights recent de-
velopments regarding manipulation of this interaction for promoting control of parasite infections.
Copyright © 2007 Mustapha Chamekh. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Arationaldesignofnewapproachesaimingtocontrolproto-
zoan infections depends not only on advances in our knowl-
edge of virulent factors, molecular pathogenesis, and im-
mune responses involved in the host defence, but also on our
understandingofﬁnelytunedco-stimulatorysignallingsthat
play a key role in immunity against infections. CD40-CD40L
interaction has emerged in the last decade as an essential
system that regulates host immune defence against infec-
tious and noninfectious diseases. CD40, a surface glycopro-
tein receptor belonging to TNF receptor family is expressed
by a number of cells including immunocompetent cells such
as professional APCs, B lymphocytes, activated CD4+ and
CD8+ T lymphocytes as well as nonhematopoetic cells [1–5].
Its ligand, CD40L, is a co-stimultory molecule that can be
expressed on various cells such as CD4+ T lymphocytes, B
lymphocytes, natural killer (NK) cells, dendritic cells (DCs),
monocytes and macrophages [6–9]. CD40-CD40L interac-
tions play an important role in the regulation of thymus-
dependant humoral immune responses through cognate in-
t e r a c t i o no fBa n dTc e l l sw h i c hp r o m o t e sBc e l lp r o l i f e r -
ation, Ig class switching, and generation of B cell memory
[10, 11]. On the other hand, CD40-CD40L interactions drive
also cell-mediated immune responses. Engagement of CD40
present on APCs with CD40L on T cells is crucial for the
priming and expansion of antigen-speciﬁc CD4+ T cells and
for the induction of costimulatory molecules on APCs [12].
It is well known that triggering of CD40 on the surface of
APCs leads to the production of cytokines, particularly IL-
12 which plays a central role in the activation of T cells to
produce IFN-γ, thereby directing cell-mediated immunity
towards Th1 subset that is required for eﬀective immunity
against intracellular pathogens [13–15]. Naturally occurring
mutation in human CD40L gene results in a defect in CD40
signalling and leads to hyper IgM syndrome. Theses patients
not only are defective in humoral immunity but also ex-
hibit impaired T cell-mediated immunity and therefore are
susceptible to infections [16, 17]. In this review, we focus
on insights provided by diﬀerent studies arguing that cell-
mediated immunity against intracellular parasites depends
upon CD40-CD40L interactions.2 Journal of Biomedicine and Biotechnology
2. CD40/CD40L INTERACTION PROMOTES
CELL-MEDIATED IMMUNITY AGAINST
PROTOZOAN INFECTIONS
2.1. Leishmania
Major insights gained into paradigms of Th-subset came
from studies on immunity to Leishmania infection. Resis-
tancetoLeishmaniawhichmultipliesasanamastigotewithin
macrophages depends on polarization of the immune re-
sponse towards Th1 type in which IL-12 and IFN-γ play a
pivotal role, while disease progression is linked to develop-
ment of Th2 type response [18]. Since CD40-CD40L inter-
action is crucial for promoting Th1 immune response, var-
ious studies were focused on the impact of such interac-
tion on the outcome of experimental infection. The ﬁrst ev-
idence for a direct role of these molecule pairs in promoting
immune responses against protozoan infections came from
studies showing that CD40- and CD40L-deﬁcient mice are
susceptible to Leishmania infections [19–21]. T cells from
these mice fail to produce IFN-γ suggesting a defect in Th1
response. Conversely, administration of IL-12 in these deﬁ-
cient mice prevents disease progression. These deﬁcient mice
were unable to mount an eﬀective immunity against par-
asite infection due to a defect in T cell mediated activa-
tion of macrophages. Beside their role in Th1 immune re-
sponse, CD40-CD40L interactions were shown also to stim-
ulate macrophages to produce number of cytokines and
inﬂammatory mediators among which Nitric Oxide (NO)
plays a key role in parasite killing [22]. Theses basic stud-
ies on Leishmania infections clearly pointed towards a ma-
jor role of CD40-CD40L interactions in skewing immune re-
sponse to Th1 type that is required for antiparasite host de-
fence.
2.2. Trypanosomacruzi
T. cruzi is an obligate intracellular parasite that invades sev-
eral types of cells in vertebrate hosts. Development of a Th1-
like immune response was sown to be associated with the
control of infection in mice [23]. In particular, IL-12, IFN-
γ,a n dT N F α play a crucial role in the development of cell-
mediated immunity against the parasite [24]. Indeed, treat-
mentofT.cruzi-infectedmicewithanti-IL-12MAbincreases
parasitemia and mortality while an exogenous supply of IL-
12confersprotectionagainstinfection[25,26].Inviewofthe
important role of IL-12, it seemed likely that CD40 ligation
is important for induction of eﬀector phases of immune re-
sponse. The potent eﬀect of the CD40-CD40L pathway in T.
cruzi infection was ﬁrst assessed by using CD40L-transfected
3T3 ﬁbroblasts to monitor parasitological and immunolog-
ical parameters in infected mice [27]. This study indicated
that supernatants of murine spleen cells stimulated with
CD40L-transfected cells prevent infection of macrophages
in vitro and this phenomenon depends on de novo pro-
duction of nitric oxide (NO). Anti-IL-12, anti-IFN-γ,a n d
anti-TNFα MAb neutralize the eﬀect of supernatants sug-
gesting the importance of these cytokines in the preven-
tion of macrophage infection. This in vitro data were further
supported by in vivo experiments showing that coinocula-
tion of CD40L-transfected 3T3 ﬁbroblasts and T. cruzi into
mice leads to reduced parasitemia and mortality and this ef-
fect is abolished by injection of anti-IL-12 MAb. Recently,
we examined further the role of CD40 ligation in T. cruzi
infection by using a new approach based on generation of
CD40L-transfectedparasitestrain[28].Miceinoculatedwith
this recombinant strain exhibit a very low parasitemia and
no mortality associated with preserved production of IFN-γ
by spleen cells compared to wild-type strain. These ﬁndings
highlight the potent role of CD40-CD40L interaction in the
stimulation of an eﬀective immunity against T. cruzi.
2.3. Toxoplasmagondii
Tachyzoites of T. gondii can disseminate in the host because
of its ability to infect many nucleated cells. Since IFN-γ is the
major cytokine required for the activation of a cell-mediated
immunity against T. gondii [29], and giving the importance
of IL-12 in the stimulation of early IFN-γ synthesis [30], one
may suspect a critical role of CD40-CD40L interaction in the
control of Toxoplasma infections. Studies performed in hu-
man with hyper IgM syndrome due to a natural CD40L mu-
tation revealed that these patients exhibited a defect in IFN-
γ s e c r e t i o ni nr e s p o n s et oT. gondii [31]. The lack of IFN-γ
production was linked to impaired IL-12 secretion, indicat-
ing that CD40-CD40L signalling was required for an opti-
mal T cell activation and production of IFN-γ. On the other
hand, Toxoplasma infection was also investigated in CD40L-
deﬁcient mice [32]. This study showed that these mice pro-
duced less IL-12 than wild type when infected with T. gondii.
Moreover, CD40L-deﬁcient mice succumbed to toxoplasmic
encephalitis indicating that these mice were not able to con-
trol parasite replication in the brain and suggesting an im-
portant role of the CD40-CD40L interaction in this process.
Furthermore, CD40 signalling was shown to regulate IFN-
γ-independent host protection against Toxoplasma infection
through TNF-α-dependant induction of macrophage an-
timicrobial activity [33]. Susceptibility of both patients with
hyper IgM syndrome and CD40L-deﬁcient mice to Toxo-
plasma infection argues for the requirement of CD40/CD40L
signalling for resistance to parasite infection.
3. MANIPULATION OF CD40 SIGNALLING AS A
POTENTIAL TOOL TO IMPROVE CONTROL
OF PROTOZOAN INFECTIONS
As reported above, CD40-CD40L interaction is crucial for
the outcome of infection in a number of intracellular par-
asite models. Stimulation of CD40 on APCs has proved to
be useful for ampliﬁcation of Th1-type response in which
IL-12 and IFN-γ play a cardinal role (Figure 1). The ﬁrst
approach used to modulate CD40 signalling was based on
agonistic anti-CD40 Ab. Injection of these Ab in mice in-
fected with Leishmania stimulates IL-12 and IFN-γ produc-
tion and induces killing of the parasites within macrophages
[34, 35]. Similarly, administration of anti-CD40L MAb in
mice infected with T. cruzi results in a stimulation of IFN-γ-
activated macrophagesto produce NOandtocontrol parasiteMustapha Chamekh 3
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Figure 1: Schematical representation of enhanced cell-mediated im-
munity against protozoan parasites through CD40-CD40L interac-
tion. Following the ﬁrst signal (1) illustrated by the recognition
of parasite peptides combined with major histocompatibility com-
plex II (MHC II) on antigen presenting cells (APC), such as den-
dritic cells, by T cell receptor (TCR) on na¨ ıve T helper cells (Th0),
and the second signal (2) which is attributed mainly to binding of
CD28/B7 molecule pairs, interaction of CD40-CD40L (3) activates
APC to produce IL-12 which promotes Th1 cell diﬀerentiation and
secretion of IFN-γ. This leads to stimulation of macrophages to
control parasite replication. This activation process can be ampli-
ﬁed by agonistic anti-CD40 antiboy, by soluble CD40L (sCD40L)
or by CD40L peptide mimetics (pep-CD40L). Transgenic para-
sites expressing CD40L can also activate CD40 signalling through
membrane-bound or secreted CD40L.
infection [27]. Although CD40L exists in nature predom-
inantly as a membrane-anchored molecule, the molecular
characterizationofCD40Lmoleculeindicatedthattheextra-
cellular carboxy-terminal region can be soluble and biolog-
ically active [6, 36]. Therefore, a variety of reports were fo-
cused on this agonistic molecule with the aim to assess its
stimulatory role in the control of parasite infection as it is
the case for other infectious diseases [14, 37]. Studies in pa-
tients with hyper IgM syndrome that exhibit deﬁcient secre-
tion of IL-12 showed that in vitro incubation of peripheral
blood mononuclear cells (PBMC) with a soluble CD40L re-
sulted in enhanced IL-12-dependant production of IFN-γ in
response to Toxoplasma gondii [31]. Soluble CD40L was also
showntoactivatemurinemacrophagesinvitrotocontrolthe
replication of T. gondii [32].
As for many adjuvant proteins, the major obstacles re-
lated to stability and issues of in vivo delivery of CD40L had
to be faced. In this regard, host cells transfected with CD40L
gene were developed as a way of delivery in diﬀerent para-
sitic models [27, 38]. Interestingly, Chen et al. described a
strategy based on directing CD40L to macrophages by co-
expressing the molecule on the surface of a cell line along
with gp63 recombinant Leishmania antigen and showed that
mice treated with these cotransfected cells produce higher
amounts of IL-12 and control the disease progression [38].
Delivery of CD40L expressed by transfected 3T3 ﬁbroblasts
was shown to reduce parasitemia in T. cruzi-infected mice
[27]. Recently, we developed a new concept based on the
use of the pathogenic organism as a vehicle for CD40L de-
livery [28]. Following transfection of T. cruzi with CD40L
gene, the encoded molecule was found properly processed
and secreted across the parasite membrane. Notably, CD40L
recombinant strain exhibited lower virulence and induced
higherINF-γ productionwheninjectedintomice.Moreover,
surviving mice resisted a challenge infection with wild-type
strain, thereby conﬁrming the vaccine adjuvant capacity of
CD40L.
The molecular characterization of CD40L and the analy-
sisofitsbindingdomainsweredeterminantstepstowardsthe
manipulation of CD40 signalling [39]. As for TNF receptors
family, the signalling through CD40 depends upon the for-
mation of a CD40L trimer complex that can each bind three
CD40 molecules [40]. Incorporation of an isoleucine zipper
motif that improves trimerization of the CD40L was shown
toenhanceitsbiologicalactivity[41].Advancesinthemolec-
ularstructuresofCD40Lbindingdomainsallowedaconcep-
tion of small CD40L mimetic molecules that could compete
with the binding of CD40L homotrimers and induce IL-12
secretion by DCs [42]. Interestingly, recent ﬁndings indicate
that when these mini-CD40L synthetic peptides were coin-
jected with T. cruzi into mice, a low parasitemia associated
with enhanced CD8+ T cells producing IFN-γ was observed
[43]. These recent reports further support the importance
of CD40L delivery as an adjuvant that can be used to drive
type 1 immune response against intracellular parasite infec-
tion (Figure 1).
Protozoan parasites have a remarkable ability to adapt
to diﬀerent host microenvironments. To make the host “as
safe as possible” for them, they have evolved many devises
among which the immunosuppression is considered as a
powerful mechanism to subvert the host’s immune response
[44]. Interfering with CD40 presentation or signalling can
be one of the powerful arms used by the parasite. Indeed,
CD40 molecules were found to be reduced in the surface
of macrophages and DCs following their infection by T.
cruzi [45, 46]. Recently, the CD40 was deﬁned as a central
molecule through which counteractive immune responses
canbetriggered[47].Basedonthecross-linkingexperiments4 Journal of Biomedicine and Biotechnology
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Figure 2: Strength of CD40-CD40L interaction can inﬂuence the out-
come of parasite infection. (a) Cross-linking of CD40 with lower
doses of agonistic anti-CD40 antibody (< 3μg/mL) on noninfected
macrophages increases phosphorylation of extracellular stress-
related kinase 1/2 (ERK 1/2) and consequently stimulates high
production of IL-10, whereas cross-linking with higher doses (>
3μg/mL) increases phosphorylation of p38-mitogen activated pro-
teinkinase(p38MAPK)andthereforestimulateshighproductionof
IL-12. (b) Cross-linking of Leishmania-infected macrophages with
intermediate dose of anti-CD40 antibody (3μg/mL) leads to pro-
duction of more IL-10 and less IL-12 than uninfected macrophages.
Thissuggeststhepotentialinvolvement ofparasitefactorsindisease
progression through stimulation of IL-10 production.
with anti-CD40 Ab on macrophages, this study indicated
that the strength of CD40 signalling activates p38-mitogen
activated protein kinase (p38MAPK) or extracellular stress-
related kinase 1/2 (ERK-1/2) signalling molecules leading
to a diﬀerential expression of IL-12 or IL-10. CD40 cross-
linking at lower doses induces activation of ERK-1/2 and
production of IL-10, a cytokine which promotes immuno-
suppression, whereas at higher doses it induces activation of
p38MAPK and secretion of IL-12 (Figure 2(a)). How such
strength of CD40 signalling is operating through interac-
tion of the immunocompetent cells and whether it can in-
ﬂuence the Th1 and Th2 immunoregulatory processes are
still unclear. Interestingly, Leishmania-infected macrophages
treatedwithanintermediate doseofanti-CD40Abproduced
more IL-10 and less IL-12 than uninfected macrophages
(Figure 2(b)),suggestingthatLeishmaniainfectionpromotes
IL-10productionthatwouldfavourdiseaseprogression[47].
This study is in line with a previous report indicating that
p38MAPK-dependant CD40 signalling is impaired in Leish-
mania-infected macrophages [35]. Overall, the involvement
of CD40 signalling in the host-parasite interaction further
exempliﬁes the reﬁned nature of the host-pathogen cross-
talk.
4. CONCLUDING REMARKS
Increasing evidence points towards the crucial role of CD40-
CD40L for the development of a cellular host protective im-
mune response against intracellular parasites. Although the
role of CD40-CD40L signalling in B cell maturation and
isotype switching is well documented, little is known about
the potent stimulation of CD40 signalling that can promote
humoral immune response against extracellular parasites. A
study on African Trypanoma infection in a model of SCID
mice reconstituted with a bovine immune system indicated
that administration of an agonistic antibody against CD40
enhanced mice survival to infection with Trypanosoma con-
golense, and was associated with increased production of
speciﬁc IgG [48]. Further studies aiming to depict accu-
rately the CD40 signalling-dependant protective Th2 immu-
nity against protozoan parasites are yet to be investigated.
The stimulation of CD40 signalling by CD40L and its deriva-
tives can be considered as a useful adjunct in a vaccine strat-
egyagainstprotozoaninfections.Currentknowledgeinhost-
parasite interaction includes a breakthrough in the modu-
lation of CD40 signalling brought about by using soluble
CD40L, CD40L-transgenic microorganisms or small peptide
mimetics of the CD40L. However, recent ﬁndings outlined
thepossibleregulationofCD40signallingbytheparasiteand
therefore stressed the need of a further understanding of the
host-pathogen crosstalk that could lead to novel approaches
for disease control.
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